KLOSTERNEUBURG, Austria & ROCKVILLE, Md.--(BUSINESS WIRE)--VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics ...
Conjugate vaccines are composed of bacterial polysaccharide antigens covalently linked to protein carriers, enabling T cell-dependent immune responses that induce high-affinity antibodies and ...
BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include ...
The pneumococcal conjugate vaccines that were studied were the PCV10 (GSK) and PCV13 (Pfizer). The saccharide in PCV10 is conjugated to nontypable Haemophilus influenzae protein D, tetanus toxoid ...
Developing and testing new treatments or vaccines for humans almost always requires animal trials, but these experiments can sometimes take years to complete and can raise ethical concerns about the ...
ROCKVILLE, MD--(Marketwire -08/20/12)- Fina Biosolutions LLC, a research and development stage biotechnology company focused on developing affordable conjugate vaccines, and The Chengdu Institute of ...
All vaccines have the same goal: disease prevention. But different vaccines reach this goal in different ways. That is, vaccine designs vary widely. Bacterial polysaccharides can be conjugated to ...
Vaxcyte aims to revolutionize the pneumococcal vaccine market with VAX-31. Click here to read an analysis of PCVX stock now.
Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...
In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback